MAPK9 is Correlated with a Poor Prognosis and Tumor Progression in Glioma

Yang, Xinyu; Jia, Qingge; Liu, Xuantong; Wu, Weidong; Yan, Han; Zhang, Zheng; Li, Mingyang; Fan, Daiming; Song, Junyang; Chen, Ligang

doi:10.31083/j.fbl2803063

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These included two risk factors (MAPK9, FSTL5) and ve protective factors (DNAJB14, CST3, GMPR2, IFI16, NEO1). MAPK9, also known as JNK2, has been demonstrated to promote tumor formation by participating in the JNK signaling pathway (36,37) , which is consistent with the results of this study. FSTL5 acts differently in different tumors; it inhibits tumor development in hepatocellular carcinoma (38) , whereas it is associated with a poor prognosis in medulloblastoma (39) .…”

Section: Discussionsupporting

confidence: 92%

Genetic variation perspective reveals potential drug targets for subtypes of endometrial cancer

Zhu,

Chen,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

The study aims to identify potential drug targets for subtypes of endometrial cancer through a Mendelian randomization study and analyze their clinical value. Data from three quantitative trait loci and Genome-wide association studies (GWAS) Meta-analysis study explored potential drug targets in endometrial cancers (including endometrioid and non-endometrioid). Complementary analysis (including network analysis, therapeutic efficacy analysis, gene differential expression, and prognosis analysis) was investigated. Furthermore, immunohistochemical staining and clinical pathological features were explored to validate potential clinical significance. Five drug targets for endometrial carcinomas, seven drug targets for endometrioid histology, and seven drug targets for non-endometrioid histology were identified, with IGF2R (OR = 1.165; 95% CI 1.067–1.272; p = 1.046 × 10− 2) and CST3 (OR = 0.523; 95% CI 0.339–0.804; p = 7.010×10− 3) demonstrating core therapeutic potential supported by causal evidence at the transcriptional, translational, and tissue-specific levels. Our research explored potential therapeutic targets associated with endometrial cancer and provided new ideas for biomarker screening and drug development.

show abstract

Section: Discussionsupporting

confidence: 92%

Genetic variation perspective reveals potential drug targets for subtypes of endometrial cancer

Zhu,

Chen,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Among the predicted mRNA targets negatively correlated with miR-644a expression ( Methods , Supplementary Table II ), MAPK9 and PTPRR emerged as the most significant candidate target genes negatively regulated by miR-644a ( Figure 2C ). MAPK9 is a kinase involved in the JNK signaling pathway and is associated with prognosis in GBM 45 , and PTPRR is a protein tyrosine phosphatase shown to inhibit ERK1/2 in prostate cancer 46 . For all downstream analyses, MAPK9 and PTPRR were used as miR-644a target genes in GBM.…”

Section: Resultsmentioning

confidence: 99%

miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma

Hong,

Wang,

Ponti

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Biological sex is an important risk factor for glioblastoma (GBM), with males having a higher incidence and poorer prognosis. The mechanisms for this sex bias are thought to be both tumor intrinsic and tumor extrinsic. MicroRNAs (miRNAs), key post-transcriptional regulators of gene expression, have been previously linked to sex differences in various cell types and diseases, but their role in the sex bias of GBM remains unknown. Methods: We leveraged previously published paired miRNA and mRNA sequencing of 39 GBM patients (22 male, 17 female) to identify sex-biased miRNAs. We further interrogated a separate single-cell RNA sequencing dataset of 110 GBM patients to examine whether differences in miRNA target gene expression were tumor cell intrinsic or tumor cell extrinsic. Results were validated in a panel of patient-derived cell models. Results: We identified 10 sex-biased miRNAs (adjusted < 0.1), of which 3 were more highly expressed in males and 7 more highly expressed in females. Of these, miR-644a was higher in females, and increased expression of miR-644a target genes was significantly associated with decreased overall survival (HR 1.3, p = 0.02). Furthermore, analysis of an independent single-cell RNA sequencing dataset confirmed sex-specific expression of miR-644a target genes in tumor cells (p < 10-15). Among patient derived models, miR-644a was expressed a median of 4.8-fold higher in females compared to males. Conclusions: Our findings implicate miR-644a as a candidate tumor cell-intrinsic regulator of sex-biased gene expression in GBM.

show abstract

MAPK9 is Correlated with a Poor Prognosis and Tumor Progression in Glioma

Cited by 2 publications

References 33 publications

Genetic variation perspective reveals potential drug targets for subtypes of endometrial cancer

Genetic variation perspective reveals potential drug targets for subtypes of endometrial cancer

miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma

Contact Info

Product

Resources

About